Drug Farm today announced that preliminary immunologic and clinical results from its Phase 1b study of DF-003, a ...
With ETX-929 and ETX-880, we are advancing potential best-in-class small molecule inhibitors against two of the most compelling targets in oncology today—KRAS and WRN. These programs, alongside our ...
Nurix Therapeutics, Inc. (NRIX) 25th Annual Needham Virtual Healthcare Conference April 13, 2026 1:30 PM EDTCompany ParticipantsArthur Sands - ...
Drug Farm today announced that preliminary immunologic and clinical results from its Phase 1b study of DF-003, a first-in-class oral ALPK1 inhibitor, will be presented in a podium session at ...
Boehringer Ingelheim today announced that The New England Journal of Medicine (NEJM) published results from the Phase 1b Beamion LUNG-1 trial of HERNEXEOS (zongertinib tablets) in treatment-naïve ...
Some researchers hold that evolution hasn’t much altered humans in the past 10,000 years. A new analysis of ancient DNA ...
In a Phase III trial, Revolution Medicines' daraxonrasib almost doubled the survival length of people with advanced ...
Lucknow Municipal Corporation to table proposal for slab-based property mutation charges, linking fees to value or size, capping ancestral transfers at Rs 5,000.
Hyderabad: One in four male breast cancer patients in the city is diagnosed at stage IV — the most advanced stage — ...
Co-primary efficacy in RAS G12–mutant PDAC included statistically significant OS and PFS gains assessed by blinded ...
Rezatapopt is a first-in-class oral therapy designed to target the TP53 Y220C mutation. This mutation affects the p53 protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results